Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System
Sign Up to like & getrecommendations! Published in 2024 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000001015
Abstract: BRAF and MEK inhibitor (BRAFi + MEKi) therapy has improved the treatment of solid tumors with BRAF mutation. However, their neurologic adverse events (nAEs) have been largely unexplored. This study aimed to provide clinicians with more updated… read more here.
Keywords: malignant melanoma; therapy; brafi meki; braf mek ... See more keywords
Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15513
Abstract: Reports suggested the potential occurrence of peripheral neuropathies (PN) in patients treated with BRAF (BRAFi) and/or MEK inhibitors (MEKi) for BRAF‐activated tumours. We aimed to better characterize these PN. We queried the French pharmacovigilance database… read more here.
Keywords: braf mek; brafi meki; treatment; neuropathies braf ... See more keywords
Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma
Sign Up to like & getrecommendations! Published in 2025 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2025-011551
Abstract: Background Resistance to BRAF and MEK inhibitors (BRAFi/MEKi) in metastatic melanoma frequently results in cross-resistance to immune checkpoint inhibitors (ICI), limiting effective treatment options. However, a subset of BRAFi/MEKi-resistant patients remains responsive to second-line ICI,… read more here.
Keywords: resistance; brafi meki; melanoma; meki resistant ... See more keywords
Abstract LB-A14: ER stress induced by 4-nerolidylcathecol (4-NC) promotes antitumor effects in BRAFi/MEKi sensitive and resistant melanoma models
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-lb-a14
Abstract: Melanoma accounts for only 4% of skin malignancies, but it has a high mortality rate. Though the specific inhibitors of MAPK pathway (BRAFi and MEKi) have revolutionized melanoma treatment, most of patients are subject to… read more here.
Keywords: melanoma; resistant melanoma; melanoma models; stress induced ... See more keywords
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-19-0672
Abstract: Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment;… read more here.
Keywords: brafi meki; pyroptosis; meki; tumor immune ... See more keywords
Triplet therapy with BRAF inhibitor, anti-EGFR agent, and MEK inhibitor in V600E BRAF–mutant colorectal cancer: A meta-analysis.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e15558
Abstract: e15558 Background: The BRAF inhibitor (BRAFi) encorafenib is currently approved in combination with the anti-EGFR agent cetuximab for patients with previously treated V600E BRAF mutant CRC (mCRC). Since resistance to BRAFi can be mediated by… read more here.
Keywords: anti egfr; brafi; brafi meki; braf ... See more keywords
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.15213
Abstract: PD-L1 is expressed by a subset of patients with metastatic melanoma (MM) with an unfavorable outcome. Its expression is increased in cells resistant to BRAF or MEK inhibitors (BRAFi or MEKi). However, the function and… read more here.
Keywords: mir; expression; brafi meki; regulation melanoma ... See more keywords
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14092123
Abstract: Simple Summary Second line anti-PD1 immunotherapy is effective in selected BRAF-mutated melanoma patients after BRAFi/MEKi immunotherapy failure. Nivolumab and pembrolizumab are of similar efficacy as a second line therapy. Worse performance status as well as… read more here.
Keywords: pd1 immunotherapy; brafi meki; anti pd1; line ... See more keywords
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15051426
Abstract: Simple Summary Patients suffering from metastasized melanoma can be treated with three different combinations of tablets (“targeted therapy”), with similar efficacy but different side effect profiles. When one of the combinations is not tolerated well,… read more here.
Keywords: brafi meki; combination; mek inhibitors; intra class ... See more keywords